Alto Neuroscience (NYSE:ANRO) Cut to Strong Sell at Zacks Research

Zacks Research lowered shares of Alto Neuroscience (NYSE:ANRO) from a hold rating to a strong sell rating in a research note released on Wednesday morning,Zacks.com reports.

A number of other brokerages also recently issued reports on ANRO. Robert W. Baird lowered their price target on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Bank of America initiated coverage on Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price objective for the company. Chardan Capital reissued a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. Wall Street Zen upgraded shares of Alto Neuroscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 18th. Finally, Wedbush raised their price target on shares of Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Price Performance

Shares of NYSE ANRO opened at $26.72 on Wednesday. Alto Neuroscience has a twelve month low of $3.00 and a twelve month high of $28.85. The firm has a market cap of $937.53 million, a P/E ratio of -11.04 and a beta of 1.04. The company has a 50 day moving average of $23.47 and a 200 day moving average of $21.50. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, research analysts expect that Alto Neuroscience will post -3.01 EPS for the current fiscal year.

Institutional Trading of Alto Neuroscience

Large investors have recently modified their holdings of the company. GK Wealth Management LLC purchased a new stake in Alto Neuroscience during the second quarter valued at $226,000. Perceptive Advisors LLC boosted its position in Alto Neuroscience by 12.6% in the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after purchasing an additional 225,500 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Alto Neuroscience by 131.5% during the 1st quarter. Bank of America Corp DE now owns 25,677 shares of the company’s stock valued at $577,000 after purchasing an additional 14,585 shares during the period. Eversept Partners LP bought a new stake in shares of Alto Neuroscience during the 1st quarter valued at about $2,814,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Alto Neuroscience during the 1st quarter valued at about $534,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.